Follow Us

Copyright 2015 Skiermont Derby LLP All Rights Reserved

Parvathi Kota, Ph.D.

P

arvathi Kota is a registered patent attorney and focuses her practice on patent litigation, inter partes review, and intellectual property transactions, with experience in preparation and prosecution of U.S. and foreign patent applications, opinion work, due diligence, and reexamination.

Parvathi has fifteen years of research experience in biochemistry, molecular biology, and plant biotechnology. She worked as a research scientist in the laboratory of Nobel Laureate Professor Har Gobind Khorana at Massachusetts Institute of Technology, where she studied structure-function relationships in rhodopsin. Her postdoctoral work focused on the genetic modification of lignin biosynthesis, and she identified new substrates for key enzymes in the lignin biosynthesis and proposed a new pathway for alfalfa. Parvathi’s doctoral dissertation focused on the purification and regulation of photosynthetic enzymes.

Parvathi has published several articles in peer-reviewed science journals, and has been invited to present her research at several national and international scientific meetings. She also served as a reviewer for the U.S. Department of Agriculture grant applications and for scientific journals. While at MIT, she taught an advanced undergraduate seminar course on G-protein coupled receptors.

Prior to joining Skiermont Derby LLP, Parvathi was an associate at Paul Hastings LLP in New York. She previously worked as a technical advisor/patent agent at Paul Hastings in New York and as a technical specialist/patent agent at Finnegan, Henderson, Farabow, Garrett & Dunner, LLP in Washington, D.C. and Cambridge.


Representative Matters

Laboratoire HRA Pharma v. Teva Pharmaceuticals USA, Inc. (District of Delaware)

Represent HRA Pharma, the branded pharmaceutical developer of ella®, in paragraph IV Hatch-Waxman patent litigation against ANDA applicant.

Andrulis Pharmaceuticals Corp. v. Celgene Corp. (District of Delaware)

Represented plaintiff pharmaceutical company in patent litigation pertaining to the use of thalidomide in combination with an alkylating agent to treat certain cancers.

Merck Sharp & Dohme Corp. v. Sandoz Inc. et al. ( District of New Jersey)

Represented Merck in a Hatch-Waxman litigation related to an anti-nausea drug Emend IV®.

Helsinn Healthcare SA et al. v. Dr. Reddy’s Laboratories Ltd. et al. (District of New Jersey)

Represented Helsinn in a Hatch-Waxman litigation related to an anti-nausea drug Aloxi®.

Eisai and Novartis v. Lupin et al. (District of Delaware)

Represented Eisai in a Hatch-Waxman litigation related to an anti-seizure drug Banzel®.

Daiichi Sankyo Inc. et al. v. Impax Laboratories Inc. et al. (District of Delaware)

Represented Daiichi Sankyo in a Hatch-Waxman litigation related to Welchol®, used for the treatment of type-2 diabetes and high cholesterol.

Takeda Pharmaceutical Co. Ltd. and Takeda Pharmaceuticals North America Inc. v. Teva Pharmaceuticals USA, Inc. and Watson Laboratories Inc. (District of Delaware)

Represented Takeda in a Hatch-Waxman litigation related to an anti-insomnia drug Rozerem®.

Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Ltd. v. Amgen Inc. (Eastern District of Pennsylvania)

Represented Amgen in a patent infringement lawsuit related to Sensipar®, used for the treatment of secondary hyperparathyroidism.

Eli Lilly & Co. v. Teva Pharmaceuticals. Inc., (Southern District of Indiana)

Represented Eli Lilly in a patent infringement lawsuit related to osteoporosis drug Evista®.

Selected Publications

Opsin is present as dimers in COS1 cells: Identification of amino acids at the dimeric interface. Proceedings of National Academy of Sciences, USA. 103, 3054-3059 (2006).

O-methylation of benzoic acid derivatives by “lignin specific” caffeic acid 3/5-O-methyltransferases. Phytochemistry 65, 837-846 (2004).

Structural basis for the modulation of lignin monomer methylation by caffeic acid/5-hydroxyferulic acid 3/5-O-methyltransferase. The Plant Cell 14, 1265-1277 (2002).

Substrate preferences of O-methyltransferases in alfalfa suggest new pathways for 3-O-methylation of monolignols. The Plant J. 25, 193-202 (2001).

Substrate preferences of caffeic acid/5-hydroxyferulic acid 3/5-O-methyltransferases in developing stems of alfalfa (Medicago sativa L.). Archives of Biochemistry and Biophysics 375, 175-182 (2000).

DALLAS
  • 1601 Elm Street, Suite 4400, Dallas, Texas 75201
  • 214.978.6600
LOS ANGELES
  • 800 Wilshire Blvd. Suite 1450
    Los Angeles, California 90017
  • 213.788.4500
Follow Us

Copyright 2016 Skiermont Derby LLP All Rights Reserved